KCNA3 and myeloid sarcoma: This procedure led to the nomination of fampridine (Fampyra®), a potassium channel blocker that is used to improve walking in adult patients with multiple sclerosis (MS) with walking disability [44], and to the conduct of an RCT that tested the potential of fampridine to modulate WM performance of healthy young adults.